• Nektar published a press release announcing the start of its Phase 3 ZENITH AD program for rezpegaldesleukin in moderate-to-severe atopic dermatitis.
• Two 510-patient registrational trials have begun; an additional 510-patient study in previously treated patients is slated to start in September.
• Initial Phase 3 topline data are expected in mid-2028; a BLA submission is targeted for 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF03777) on July 21, 2026, and is solely responsible for the information contained therein.